Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18039231 | 0.86 | TDP1 (0.40) | TDP1CNR2CNR1MAPTNR1H4 | |
| SCHEMBL6388980 | 0.85 | TDP1 (0.46) | TDP1LMNASMN1; SMN2ALDH1A1CCR5 | |
| SCHEMBL528429 | 0.84 | TDP1 (0.47) | TDP1LMNASMN1; SMN2ALDH1A1CCR5 | |
| SCHEMBL6393147 | 0.83 | TDP1 (0.42) | TDP1CNR2CNR1MAPTNR1H4 | |
| SCHEMBL6388251 | 0.81 | CNR2 (0.43) | TDP1CNR2CNR1MAPTNR1H4 | |
| SCHEMBL528965 | 0.79 | CETP (0.48) | TDP1CNR2GAAALDH1A1ITGB1 | |
| SCHEMBL528968 | 0.79 | CETP (0.48) | TDP1MAPTNR1H4SMN1; SMN2ALDH1A1 | |
| SCHEMBL6386887 | 0.78 | TDP1 (0.48) | TDP1LMNASMN1; SMN2ALDH1A1CCR5 | |
| SCHEMBL528667 | 0.78 | TDP1 (0.46) | TDP1LMNASMN1; SMN2ALDH1A1CCR5 | |
| SCHEMBL527982 | 0.77 | TDP1 (0.42) | TDP1CNR2CNR1NR1H4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3833336-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DalCor Pharma UK Ltd Leatherhead, Zug Branch (CH) | 2021-06-16 | — | — | EP | claimed |
| WO-2020030814-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2020-02-13 | — | — | WO | claimed |
| WO-2019043018-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH (CH) | 2019-03-07 | — | — | WO | claimed |
| EP-3261628-A1 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION IN THE TREATMENT OF CANCER | King Abdullah University Of Science And Technology (SA) | 2018-01-03 | — | — | EP | claimed |
| WO-2016135633-A1 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION IN THE TREATMENT OF CANCER | KING ABDULLAH UNIVERSITY OF SCIENCE & TECHNOLOGY (SA) | 2016-09-01 | — | — | WO | claimed |
| EP-2598158-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | Institut de Cardiologie de Montréal (CA) | 2013-06-05 | — | — | EP | claimed |
| WO-2012012870-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2012-02-02 | — | — | WO | claimed |
| EP-1603553-A2 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | JAPAN TOBACCO INC. (JP) | 2005-12-14 | — | — | EP | claimed |
| WO-2004082593-A2 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | JAPAN TOBACCO INC. (JP) | 2004-09-30 | — | — | WO | claimed |
| EP-3833336-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DalCor Pharma UK Ltd Leatherhead, Zug Branch (CH) | 2021-06-16 | — | — | EP | disclosed |
| WO-2020030814-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2020-02-13 | — | — | WO | disclosed |
| WO-2019043018-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH (CH) | 2019-03-07 | — | — | WO | disclosed |
| EP-3261628-A1 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION IN THE TREATMENT OF CANCER | King Abdullah University Of Science And Technology (SA) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016135633-A1 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION IN THE TREATMENT OF CANCER | KING ABDULLAH UNIVERSITY OF SCIENCE & TECHNOLOGY (SA) | 2016-09-01 | — | — | WO | disclosed |
| EP-2598158-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | Institut de Cardiologie de Montréal (CA) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012012870-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2012-02-02 | — | — | WO | disclosed |
| EP-1603553-A2 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | JAPAN TOBACCO INC. (JP) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004082593-A2 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | JAPAN TOBACCO INC. (JP) | 2004-09-30 | — | — | WO | disclosed |